| Literature DB >> 27143438 |
Elisanne A L M Biemans1, Nanda M Verhoeven-Duif2, Johan Gerrits2, Jurgen A H R Claassen3, H Bea Kuiperij1, Marcel M Verbeek4.
Abstract
Cerebrospinal fluid (CSF) levels of d-serine were recently reported as a potential new biomarker for Alzheimer's disease (AD), showing a perfect distinction between AD patients and healthy controls. In this study, we aimed to confirm these results and extend these previous findings to dementia with Lewy bodies and frontotemporal dementia. d-Serine levels in CSF of 29 AD patients, 8 dementia with Lewy bodies patients, 14 frontotemporal dementia patients, and 28 nondemented controls were measured using ultra-high-performance liquid chromatography-tandem mass spectrometry. In contrast to previous findings, in our study CSF d-serine levels were only slightly increased in AD patients compared with controls. CSF d-serine in AD did not differ from other dementias and was also not correlated to mini-mental state examination-scores. Owing to the large overlap of d-serine levels, we conclude that CSF d-serine is neither a suitable biomarker for AD nor for cognitive decline.Entities:
Keywords: Alzheimer's disease; Biological markers; Cerebrospinal fluid; Dementia with Lewy bodies; Frontotemporal dementia; d-serine
Mesh：
Substances：
Year: 2016 PMID： 27143438 DOI： 10.1016/j.neurobiolaging.2016.03.017
Source DB: PubMed Journal: Neurobiol Aging ISSN： 0197-4580 Impact factor: 4.673